Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
c-Myc Antibody (MYC275 + MYC909), DyLight 405, Novus Biologicals™
Mouse Monoclonal Antibody
Supplier: Novus Biologicals NBP247739V
Description
c-Myc Monoclonal specifically detects c-Myc in Human samples. It is validated for Flow Cytometry, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin, Immunofluorescence.Specifications
c-Myc | |
Monoclonal | |
DyLight 405 | |
50mM Sodium Borate with 0.05% Sodium Azide | |
MYC | |
Recombinant human c-Myc protein (Uniprot: P01106) | |
Protein A or G purified | |
Autophagy, Cancer, Cancer Stem Cells, Cell Cycle and Replication, Chromatin Research, Core ESC Like Genes, Epigenetics, Epitope Tags, Stem Cell Markers, Transcription Factors and Regulators, Tumor Suppressors | |
4609 | |
Human | |
Purified |
Flow Cytometry, Immunohistochemistry, Immunohistochemistry (Paraffin), Immunofluorescence | |
MYC275 + MYC909 | |
Flow Cytometry, Immunohistochemistry, Immunohistochemistry-Paraffin, Immunofluorescence | |
avian myelocytomatosis viral oncogene homolog, BHLHE39, bHLHe39MRTL, Class E basic helix-loop-helix protein 39, c-Myc, MYC, myc proto-oncogene protein, MYCC, myc-related translation/localization regulatory factor, Proto-oncogene c-Myc, Transcription factor p64, v-myc avian myelocytomatosis viral oncogene homolog, v-myc myelocytomatosis viral oncogene homolog (avian) | |
Mouse | |
63 kDa | |
0.1 mL | |
Primary | |
It recognizes a transcription factor of 64-67kDa, identified as c-myc. This monoclonal antibody shows no cross-reaction with v-myc. c-myc is involved in the control of cell proliferation and differentiation and is amplified and/or over-expressed in a variety of tumors. Over-expression of c-myc protein occurs frequently in luminal cells of prostate intraepithelial neoplasia as well as in most primary carcinomas and metastatic disease. Rearrangement of the MYC gene is found in 3% to 16% of diffuse large B-cell lymphoma (DLBCLs) and in nearly 100% of Burkitt lymphomas (BL). Identifying MYC status is important in establishing final diagnosis of DLBCL, BL, or B-cell lymphoma, with features intermediate between DLBCL and BL as well as in differential diagnoses of the lymphomas. | |
Store at 4C in the dark. | |
IgG1 κ |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?
Product Content Correction